Filing Overview
This Form 8-K was filed by Blue Water Biotech, Inc. (now identified in the request metadata as Onconetix, Inc.) and signed October 3, 2023. The report concerns events occurring from September 20 through October 3, 2023. The filing date and stated report date should be verified because the filing includes events after September 21, 2023.
Material Agreements and Transactions
- Cardinal Health distribution agreement: Effective September 20, 2023, the company appointed Cardinal Health 105, LLC as its exclusive third-party logistics distribution agent for sales of all commercial assets.
- The agreement has an initial three-year term and automatically renews for additional one-year terms unless terminated under its provisions.
- Fees include a one-time $15,500 startup fee, a $7,000 monthly account-management fee, and additional charges for implementation, information systems, warehouse operations, financial services, and other services.
- Veru asset purchase amendment: On September 29, 2023, the company amended its April 19, 2023 asset purchase agreement for ENTADFI.
- The required $4 million installment payment due by September 30, 2023 was restructured. The obligation was deemed fully satisfied through a $1 million cash payment made September 29, 2023, plus the issuance of 3,000 shares of Series A Convertible Preferred Stock by October 3, 2023.
Preferred Stock Terms and Potential Dilution
- Each Series A Preferred share has a $1,000 stated value and is convertible by Veru after one year from issuance at an initial conversion price of $0.5254 per common share, subject to adjustments and shareholder-approval limitations.
- The 3,000 preferred shares are initially convertible into approximately 5,709,935 common shares, subject to the applicable limitations and adjustments.
- The preferred stock participates ratably in common-stock dividends on an as-converted basis, has limited voting rights, and has a liquidation preference of $1,000 per share plus accrued and unpaid dividends.
- The company may redeem the preferred stock in whole or in part at its option.
- The company agreed to use commercially reasonable efforts to obtain required shareholder approval by December 31, 2023 and to include the underlying common shares in its next resale registration statement.
- The preferred stock was to be issued without registration under the Securities Act in reliance on the Section 4(a)(2) private-placement exemption.
Financial and Operating Impact
The filing does not provide revenue, profit, cash-flow, margin, debt, liquidity, or balance-sheet amounts. It discloses a $1 million cash payment to Veru, a $15,500 Cardinal Health startup fee, a $7,000 monthly account-management fee, and other unspecified distribution-related fees. The preferred-stock issuance satisfies the remaining portion of the $4 million installment obligation but may create substantial future common-stock dilution.
Outlook, Risks, and Unusual Items
- Commercial distribution will depend on Cardinal Health’s logistics and related services under the new agreement.
- The filing does not provide sales guidance, product-revenue forecasts, or profitability guidance.
- Conversion of the preferred stock is subject to a one-year waiting period, adjustment provisions, and shareholder-approval limitations.
- Failure to obtain shareholder approval or complete the planned resale registration could affect Veru’s ability to convert or resell the underlying common shares.
- The filing references the company’s commercial assets and ENTADFI but does not quantify expected demand, inventory commitments, or implementation costs.
Key Facts Investors Should Verify
- Whether the registrant’s current legal name is Onconetix, Inc. or Blue Water Biotech, Inc., and the effective timing of any name change.
- The actual issuance date of the 3,000 Series A Preferred shares and the final conversion terms in the Certificate of Designations.
- Whether shareholder approval for conversion was obtained by December 31, 2023.
- The number of common shares ultimately issuable to Veru after adjustments and applicable Nasdaq or shareholder limitations.
- The full Cardinal Health fee schedule, termination provisions, and any minimum-volume or other commercial commitments.
- The company’s subsequent liquidity, cash needs, and ability to fund ENTADFI commercialization.